Created in 2004, Trasis provides hospital suppliers with the means to produce radiolabelled compounds. Trasis products consist of synthesizers, dispensers, and consumables. Our objective: to facilitate introduction of the newest radiopharmaceuticals into clinical practise.

Currently present in about one third of the world's radiopharmacies thanks to its bestseller the AllinOne synthesizer, Trasis has now grown to more than 280 employees, having 60 engineers and chemists in R&D alone. An EU-GMP Part 1 and Part 2 certified company, Trasis opened a US subsidiary in 2020 and currently invests 16% of its turnover into R&D.

Due to this growth, Trasis undertook, in 2021, the construction of new facilities that will add an additional 5,000 square meters to the existing ones, which will be inaugurated in April 2024. This dynamism is directly linked to Trasis' know-how involving a highly diversified staff with expertise in process automation, synthetic and analytical chemistry, regulatory affairs, software engineering, mechanical design, plastics component engineering, clean room operations, customer service, etc.



© Trasis

Trasis product range

Trasis offers four types of products meeting the needs of all stages of radiopharmaceutical production and administration:

- Synthesizers allowing for the production of pharmaceutical molecules labelled with radionuclides.
- Instruments for radiopharmaceuticals quality control.
- Dispensers for the preparation and administration of radioactive drugs designed for minimal exposure to medical staff.
- Consumables such as drug-specific cassettes and reagent kits for the synthesizers, and sterile sets/syringe-like cartridges for the dispensers.

Radiopharmaceutical applications and innovations

Radio-labelled pharmaceutical substances are used for medical imaging, such as PET, mainly in

oncology but increasingly in neurology and cardiology. The main users of these systems are radiopharmaceutical production networks and university hospitals. In particular, systems for the preparation and administration of single patient radiopharmaceutical doses such as the Trasis Unidose machine, prepare customised doses on demand and provide unparalleled radiation protection for medical staff. A new generation of these systems designed to be more attractive and affordable is currently under development.

In 2023, Trasis has expanded its range of instruments by introducing two new devices to the market: the latest addition to the synthesizer family, AllinOne S, doubles the production capacity of radiopharmaceuticals, while the compact QC1 ensures quality control with fewer operator interventions and in under 30 minutes.

Strategic expansion and collaborations

© Trasis

In addition, Trasis has expanded its offering by integrating Eras Labo, which joined the Trasis Group at the end of 2022. The acquisition of this Grenoble-based company, specialized in the manufacture of precursors, enables Trasis to secure part of its supply chains and represents a sought-after diversification opportunity beyond the radiopharmaceutical sector.

Trasis partners such as ULiège and Erasmus Hospital in Brussels offer nearby academic laboratories where cyclotrons produce radionuclides on a daily basis. These collaborations allow the company to test, develop, and improve radiochemistry processes. In addition, Trasis is in contact with research centres and drug companies around the world developing radiopharmaceutical drugs of the future. These drugs now include therapeutic compounds which, once injected into the bloodstream, bind specifically with various tumour cells proving to be very effective and giving new hope to many patients.

© Trasis

Trasis
Rue Gilles Magnée 90 – B-4430 Ans
Tel.: +32 (0)4 365 86 57
Email: info@trasis.com – https://trasis.com/